Lung Cancers News
In 60-year follow-up, significantly lower lung cancer rates seen for those with childhood BCG vaccination.
Preclinical and emerging clinical evidence support the possible use of AMG 510 as a single-agent KRAS (G12C) inhibitor, but preclinical evidence may also support the agent in combination.
Patients with advanced non-small cell lung cancer who did not have disease progression after chemoradiotherapy appeared to have a long-term survival benefit with durvalumab.
Patients with NSCLC who did not respond to immune checkpoint blockade had unique molecular characteristics, revealing possible therapeutic targets.
In fit men, mortality lower in smokers with lung cancer, lung cancer risk lower in former smokers.
No significant differences in PROs were observed among patients treated with subsequent durvalumab after chemoradiation therapy for stage III unresectable NSCLC compared with those who received subsequent placebo.
Among patients who were naive to ALK inhibition, the overall response rate was 83% for the 450-mg dose and 60% for the 300-mg dose.
Palliative care and end-of-life needs were not addressed for approximately 40% of simulated patients who would have been eligible for this approach.
Screening patients with lung cancer using low-dose computed tomography (LDCT) has been associated with reducing lung cancer mortality as much as 20%, but the technique remains limited.
Occupational exposure account for 30% of all lung cancer diagnosis in the United States.
Next-generation sequencing of circulating tumor DNA (ctDNA) may identify patients who are likely to benefit from targeted therapy for NSCLC.
Researchers found that molecular profiles of patients with KRAS-mutant NSCLC differ among patients from various racial groups.
Cost of therapy was a major concern among a majority (69%) of patients with lung cancer who responded to the survey.
Researchers identified and validated novel risk groups models that predict OS and PFS among NSCLC patients treated with immunotherapy.
Researchers examined real-life outcomes with the PACIFIC paradigm and found that the higher incidence of pneumonitis did not affect overall survival.
Researchers also found differences in the composition of the gut microbiome between patients with lung cancer who experienced toxicity and those who did not.
Point-of-service counseling in a lung cancer screening program led some patients to quit and many patients to reduce their cigarette usage.
Researchers observed 4 patients whose brain lesions were completely resolved by treatment with capmatinib.
A phase 1 trial found that AMG 510 is tolerated in patients with previously treated non-small cell lung cancer.
Researchers found that NLR before treatment was significantly associated with overall survival and progression-free survival.